Harnessing the power of genomics to identify novel drug targets for diseases with significant unmet need.
Published 7 Oct 2020 |
1 min read
Genomics plc has a major multi-year partnership with Vertex Pharmaceuticals, to use our understanding of human genetics and machine learning to improve the discovery of targets for precision medicines, and to advance the understanding of the clinical impact of human genetic variation and patient stratification in diseases with significant unmet need.
Our goal is to advance Vertex’s efforts to develop transformative precision medicines for people with serious diseases. Scientists from Vertex and Genomics plc work closely together to incorporate their deep understanding of human genetics into research and development related to target discovery and target validation in certain diseases.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programmes in cystic fibrosis, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.